What is StimOxyGen?
StimOxyGen is a pioneering biotechnology enterprise dedicated to overcoming the physiological barriers that limit the success of conventional cancer therapies. The company's core innovation involves the development of pH-sensitive nanoparticle formulations that effectively deliver oxygen to hypoxic regions within solid tumors. This mechanism is critical, as hypoxia is a well-documented factor in tumor resistance to both radiation and chemical treatments. By collaborating with academic institutions such as Ulster University, StimOxyGen bridges the gap between fundamental scientific research and clinical application. The company operates at the intersection of life sciences and advanced materials, positioning itself as a key player in the next generation of precision oncology tools designed to improve patient survival rates and treatment durability.
How much funding has StimOxyGen raised?
StimOxyGen has raised a total of $1.9M across 1 funding round:
Other Financing Round
$1.9M
Other Financing Round (2025): $1.9M with participation from Clarendon Fund Managers, QUBIS, Innovate UK Business Connect, and DSW Ventures
Key Investors in StimOxyGen
Clarendon Fund Managers
Clarendon Fund Managers is a specialized venture capital firm that provides equity finance to high-growth businesses in Northern Ireland, managing significant regional funds to support early-stage development.
QUBIS
QUBIS Ltd focuses on transforming high-quality research from Queens University, Belfast into commercially viable spinoff companies, with a strong emphasis on the life sciences and technology sectors.
DSW Ventures
DSW Ventures is a UK-based venture capital firm that invests in innovative regional startups, providing hands-on support to founders in the software and spin-out sectors.
What's next for StimOxyGen?
With the successful closure of this major enterprise-level funding, StimOxyGen is poised to transition from its current research-heavy phase into more rigorous clinical validation and scaling. The strategic roadmap likely includes expanding its intellectual property portfolio and deepening its collaborative research efforts to refine its nanoparticle delivery systems. As the company navigates the complexities of the biotech regulatory landscape, the focus will remain on demonstrating the scalability of its oxygen-generating technology. Investors are expected to monitor the firm's progress in translating laboratory success into tangible clinical data, which will be essential for future commercialization efforts and potential partnerships with larger pharmaceutical entities. The current capital structure provides the necessary runway to achieve these critical milestones, ensuring that StimOxyGen remains at the forefront of hypoxia-targeting therapeutic innovation.
See full StimOxyGen company page
